Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

n reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section in Genzyme's Quarterly Report on Form 10-Q for the period ended March 31, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise these statements.

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800- 905-4369 within the United States or 1-703-797-1866 outside the United States.

    Media Contact:       Investor Contact:

    Dan Quinn            Catie Forte

    (617) 768-6849       (617) 768-6881

CONTACT: media, Dan Quinn, 617-768-6849, or investors, Catie Forte,617-768-6881

Web site: http://www.genzyme.com//

Company News On-Call: http://www.prnewswire.com/comp/113803.html /

Ticker Symbol: (NASDAQ-NMS:GENZ)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/19/2014)... N.J. , Sept. 19, 2014 Merck (NYSE: ... States and Canada , is teaming ... Desafiando La Diabetes: Logra Tus Metas , an educational program encouraging ... blood sugar -- a key treatment goal to help reduce the ... States are at a higher risk for developing type ...
(Date:9/19/2014)... , Sept. 19, 2014 Larry J. Merlo ... CVS ), will speak before the National Press Club in ... the company,s recent move to stop selling tobacco products and ... future of health. "Dramatic changes in our health ... providers and government," Merlo has said. "CVS Health has a ...
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... collagenase-based products marketed as XIAFLEX ® in the U.S. ... BioSpecifics, President, Tom Wegman , will present a corporate ... the Biotech Industry Conference. The presentation will ... EDT at the Millennium Broadway Hotel in New ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... , AT A GLANCE , Positron emission mammography ... ability to differentiate between benign and cancerous lesions. ... of suspicious lesions found. , An NIH-sponsored, ... cancer found that Positron Emission Mammography (PEM) scanners significantly ...
... , WOODCLIFF LAKE, N.J., Oct. 29 Eisai Inc. and ... the recipient of the 2009 C.A.R.E. Pharmacy Award. ... Greene is being recognized for the critical role she has ... Alzheimer,s disease. As a Geriatric Consultant Pharmacist with the ...
Cached Medicine Technology:High-Resolution Breast PET Improves Breast Cancer Detection 2High-Resolution Breast PET Improves Breast Cancer Detection 3Eisai Inc. and the Alzheimer's Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimer's Disease 2Eisai Inc. and the Alzheimer's Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimer's Disease 3
(Date:9/19/2014)... 2014 Unbound , an international humanitarian ... regions of the Philippines being affected by both a tropical ... families evacuated to the nearest public schools while others moved ... and gusty winds to portions of the northern Philippines. ... homes filled with more than 10 feet of water. ...
(Date:9/19/2014)... of human cancers have abnormally upregulated chemical signals ... are controlled during tumor formation is not fully ... Fayngerts, PhD, both researchers in the department of ... of Medicine, University of Pennsylvania, and colleagues report ... cancer by targeting these pathways. , Lipid second ...
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... The Alliance for Bangladesh Worker ... National Fire Protection Association (NFPA), a recognized international ... in a Memorandum of Understanding signed by both ... other stakeholders with information, guidance and access to ... and safety of workers in ready-made garment (RMG) ...
Breaking Medicine News(10 mins):Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:New cancer drug target involving lipid chemical messengers 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3
... whether antiretroviral medications normally used to treat HIV infection ... as a vaginal gel or taken as oral tablets ... to Control the Epidemic (VOICE) or MTN-003, will involve ... infection in four African countries. The trial will test ...
... that some of the same antiretroviral (ARV) drugs used to ... Microbicide Trials Network have enrolled the first participants into a ... in women. The VOICE Study Vagina and Oral ... applying a vaginal microbicide gel containing an ARV every day ...
... , , ADDISON, ... announced today the presentation of results from the first ... in Washington D.C. September 16-18. The recently completed clinical study compared ... either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing. ...
... Essman, acting on behalf of Hard to Treat Diseases, ... the actions of certain retail brokers who restricted trading ... these matters is sponsored by Investor Relations firm Mina ... Mina Mar is currently suing a stock chat board ...
... extend life and reduce risk of physical disability, researchers find ... who get regular exercise may live longer and be at ... , The research included almost 1,900 people born in 1920 ... 85. Those who did less than four hours of physical ...
... odds of disease, study shows, , WEDNESDAY, Sept. 16 ... replacement therapy women take to relieve menopausal symptoms seem ... face, a new French study suggests. , Overall, ... the risk of breast cancer, even when only used ...
Cached Medicine News:Health News:Clinical trial of antiretroviral-based HIV prevention strategies for women now under way 2Health News:Clinical trial of antiretroviral-based HIV prevention strategies for women now under way 3Health News:VOICE study, a major HIV prevention trial for women, is launched in Zimbabwe 2Health News:VOICE study, a major HIV prevention trial for women, is launched in Zimbabwe 3Health News:VOICE study, a major HIV prevention trial for women, is launched in Zimbabwe 4Health News:ULURU Inc. Presents Results of First Randomized Clinical Trial for Altrazeal(TM) at the Symposium on Advanced Wound Care (SAWC) Fall Meeting in Washington D.C. 2Health News:Hard to Treat Diseases, Inc. (HTDS) Attorney Brad Essman Uncovers Reports of Retail Brokers Making False Statements 2Health News:Hard to Treat Diseases, Inc. (HTDS) Attorney Brad Essman Uncovers Reports of Retail Brokers Making False Statements 3Health News:Hard to Treat Diseases, Inc. (HTDS) Attorney Brad Essman Uncovers Reports of Retail Brokers Making False Statements 4Health News:Exercise Benefits Even the Oldest Old 2Health News:Timing, Type of HRT May Determine Breast Cancer Risk 2Health News:Timing, Type of HRT May Determine Breast Cancer Risk 3
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
ManuTrain is an active wrist support that has optional features for increased stabilization....
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint uses ... the hand with ulnar deviation at the ... grasp or pinch. Radial and ulnar polycentric ... unimpeded flexion and extension. Padded, malleable finger ...
Medicine Products: